Citation Impact
Citing Papers
Probing mucin-type O-linked glycosylation in living animals
2006 StandoutNobel
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Nuclear Lamin-A Scales with Tissue Stiffness and Enhances Matrix-Directed Differentiation
2013 StandoutScience
Hallmarks of Cancer: The Next Generation
2011 Standout
Methylation and silencing of the retinoic acid receptor-β2 gene in cervical cancer
2002
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
1998
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
A Dose-Escalating Study of Weekly Bolus Topotecan in Previously Treated Ovarian Cancer Patients
2001
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Immortalization and Transformation of Human Cells by Human Papillomavirus
1994
Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.
1995
AGN193109 Is a Highly Effective Antagonist of Retinoid Action in Human Ectocervical Epithelial Cells
1996
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Renal-Cell Carcinoma
1996 Standout
Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
1993
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
1998
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
A phase II trial of ZD0473 in platinum-pretreated ovarian cancer
2002
Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer
1997
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Retinoids in cancer therapy.
1992
Ectopic Expression of Nonliganded Retinoic Acid Receptor β Abrogates AP-1 Activity by Selective Degradation of c-Jun in Cervical Carcinoma Cells
2004 StandoutNobel
Biology of Natural Killer Cells
1989 Standout
Papillomaviruses and cancer: from basic studies to clinical application
2002 StandoutNobel
The impact of T‐cell immunity on ovarian cancer outcomes
2008
Revealing the human mucinome
2022 StandoutNobel
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK
2002
Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance
2001
Prevention of Venous Thromboembolism
2004 Standout
Infectious and immunosuppressive complications of purine analog therapy.
1995
The promise of retinoids to fight against cancer
2001
Angiogenesis and Vascular Functions in Modulation of Obesity, Adipose Metabolism, and Insulin Sensitivity
2013
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
2003 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Head and Neck Cancer
1993 Standout
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
2010
Prevention of Venous Thromboembolism
2008 Standout
What We Talk About When We Talk About Fat
2014 Standout
Selective Inhibitors of Glutathione Transferase P1 with Trioxane Structure as Anticancer Agents
2015
Glycocalyx Engineering with a Recycling Glycopolymer that Increases Cell Survival In Vivo
2015 StandoutNobel
Mucins in cancer: protection and control of the cell surface
2003
Phase II Trial of Vinorelbine in Recurrent and Progressive Epithelial Ovarian Cancer
1999
Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
2003 Standout
Tumor Angiogenesis
2008 Standout
Anemia of Chronic Disease
2005 Standout
Cancer of the Ovary
2004 Standout
Hierarchical Assembly of Model Cell Surfaces: Synthesis of Mucin Mimetic Polymers and Their Display on Supported Bilayers
2007 StandoutNobel
Topotecan Has Substantial Antitumor Activity as First-Line Salvage Therapy in Platinum-Sensitive Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study
2000
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
2006 StandoutScience
A systems approach to cancer therapy
1996
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Retinoic acid and interferon combination studies in human cancer
1993
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2002 StandoutScience
Density Variant Glycan Microarray for Evaluating Cross-Linking of Mucin-like Glycoconjugates by Lectins
2012 StandoutNobel
Multi-institutional Phase 2 Study of TLK286 (TELCYTA, a Glutathione S-transferase P1-1 Activated Glutathione Analog Prodrug) in Patients With Platinum and Paclitaxel Refractory or Resistant Ovarian Cancer
2006
Second-Line Treatment of Ovarian Cancer
2000
Granulosa Cell Tumor of the Ovary
2003
Identification of an IL-10-Producing HLA-DR-Negative Monocyte Subset in the Malignant Ascites of Patients with Ovarian Carcinoma That Inhibits Cytokine Protein Expression and Proliferation of Autologous T Cells
1999
Randomized Phase II/III Trial of Interferon Alfa-2a With and Without 13-cis-Retinoic Acid in Patients With Progressive Metastatic Renal Cell Carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951)
2005
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
Functional Role of Type I and Type II Interferons in Antiviral Defense
1994 StandoutScience
Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells
2002 StandoutNobel
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
2012 StandoutNobel
RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation.
1995
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
2001
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
2001 Standout
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
2003
Chemically tunable mucin chimeras assembled on living cells
2015 StandoutNobel
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma
1999
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Cytokine therapeutics: lessons from interferonalpha.
1994
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
2007
Interfacing Carbon Nanotubes with Living Cells
2006 StandoutNobel
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
2005 Standout
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Noncovalent Cell Surface Engineering: Incorporation of Bioactive Synthetic Glycopolymers into Cellular Membranes
2008 StandoutNobel
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
Works of J. J. Kavanagh being referenced
Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients.
1988
Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides.
1997
Recurrent ovarian granulosa cell tumor: a case report of a dramatic response to Taxol
1995
Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trials
1995
Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
1997
Venous thromboembolism syndrome in gynecological cancer
2006
GnRH antagonists in the treatment of gynecological and breast cancers.
2003
13-cis-Retinoic Acid Plus Interferon- 2a in Locally Advanced Squamous Cell Carcinoma of the Cervix
1993
Multi-institutional phase 2 study of TLK286 (TELCYTAtm, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer
2005
13-cis-Retinoic Acid Plus Interferon -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix
1992
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
1996
Clinical Pharmacology, Metabolism, and Tissue Distribution of 90Y-Labeled Monoclonal Antibody B72.3 After Intraperitoneal Administration
1991
Phase II trial of fludarabine in patients with epithelial ovarian cancer.
1986
Interferon-alpha 2a, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study.
1998
Tamoxifen therapy of epithelial ovarian cancer
1986
Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines
1998
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
2000
Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer.
1996
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.
1997
Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor.
1996
Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy.
1989